Siglec-9 is a sialic-acid-binding lectin expressed predominantly on myeloid cells. Aberrant glycosylation occurs in essentially all types of cancers and results in increased sialylation. Thus, when the mucin MUC1 is expressed on cancer cells, it is decorated by multiple short, sialylated O-linked glycans (MUC1-ST). Here we found that this cancer-specific MUC1 glycoform, through engagement of Siglec-9, 'educated' myeloid cells to release factors associated with determination of the tumor microenvironment and disease progression. Moreover, MUC1-ST induced macrophages to display a tumor-associated macrophage (TAM)-like phenotype, with increased expression of the checkpoint ligand PD-L1. Binding of MUC1-ST to Siglec-9 did not activate the phosphatases SHP-1 or SHP-2 but, unexpectedly, induced calcium flux that led to activation of the kinases MEK-ERK. This work defines a critical role for aberrantly glycosylated MUC1 and identifies an activating pathway that follows engagement of Siglec-9.
Cancers have developed a plethora of mechanisms to evade the immune response, including the initiation of a permissive local environment. For cancer cells to remodel their microenvironment, they need to acquire changes that include the recruitment and 'education' of monocytes and the repolarization of resident macrophages 1 . Macrophages are phenotypically plastic, and factors produced by cancer cells can polarize macrophages to become tumor-promoting cells. These 'tumor-educated' macrophages promote the growth of and invasion by cancer cells by contributing to all the stages involved in cancer dissemination; this cumulates in metastasis 2 .
Changes in glycosylation occur in essentially all types of cancers, and changes in mucin-type O-linked glycans result in the most prevalent aberrant glycophenotypes in which increased sialylation often occurs 3, 4 . Expression of the transmembrane mucin MUC1 is upregulated in breast and the majority of adenocarcinomas and, due to the presence of a variable number of tandem repeats that contain the O-linked-glycosylation sites, MUC1 can carry from 100 to over 750 O-glycans 5 . Due to the aberrant glycosylation present in cancer, the multiple O-linked glycans carried by MUC1 are mainly short and sialylated 3, 6 , in contrast to the long, branched chains seen on MUC1 expressed by normal epithelial cells 7 . In carcinomas, the aberrant O-linked glycosylation of MUC1 can alter the interaction of MUC1 with lectins of the immune system 8 and can thereby influence tumorimmune system interplay. While it is clear that expression of MUC1 carrying short, sialylated core 1 glycans (NeuAcα2,3Galβ1-3GalNAc) (MUC1-ST) enhances tumor growth 9, 10 , the mechanisms underlying this increased growth are ill defined. However, the immune system seems to serve a role in this, as syngeneic mouse tumor cells expressing MUC1-ST grow much faster in mice with transgenic expression of MUC1 than do the same cells expressing MUC1 carrying branched core 2 glycans associated with normal glycosylation, while this differential growth is not seen in immunosuppressed mice 9 .
Siglecs ('sialic-acid-binding immunoglobulin-like lectins') are a family of sialic-acid-binding lectins that, except for Siglec-4, are expressed on various cells of the immune system 11 . The cytoplasmic domains of most Siglecs contain immunoreceptor tyrosine-based inhibitory motifs (ITIMs) that recruit the tyrosine phosphatases SHP-1 and SHP-2 (ref. 12 ) and thus regulate the cells of the innate and adaptive immune responses 13 . It has become clear that Siglecs have a role in cancer immunosuppression, as the hyper-sialylation seen in cancers induces binding to these lectins [14] [15] [16] . MUC1 expressed by cancer cells has been shown to bind to Siglec-9; this results in the recruitment of β-catenin to the cytoplasmic tail of MUC1, which induces its translocation to the nucleus and increased tumor cell growth 17 . That work focused on the effect of the interaction with Siglec-9 on the MUC1-expressing cancer cells 17 . In contrast, we have used a defined glycoform of MUC1 (ref. 18) to investigate the effect of this interaction on Siglec-9-expressing immune cells. Siglec-9 is expressed predominantly on myeloid cells and has a 'preference' for sialic acid α2,3 linked to galactose 19 . Here we found that MUC1 carrying the sialylated core 1 glycan (MUC1-ST), a glycan not found on this mucin expressed by normal epithelial cells, bound to Siglec-9 on primary 1 2 7 4 VOLUME 17 NUMBER 11 NOVEMBER 2016 nature immunology A r t i c l e s human monocytes and macrophages and induced a secretome signature (the proteins released by a cell) unique to each cell type. Moreover, when MUC1-ST bound to Siglec-9 expressed by primary macrophages, a tumor-associated macrophage (TAM) phenotype was actively induced, as shown by the inhibition of CD8 + T cell proliferation and upregulation of the expression of indoleamine 2,3-dioxygenase (IDO), the scavenger receptor CD163, the mannose receptor CD206 and the immunological checkpoint ligand PD-L1.
RESULTS

MUC1-ST binds to Siglec-9 expressed by myeloid cells
To investigate the interaction of MUC1-ST with cells of the immune system, we isolated immune-cell subsets from donor blood and incubated the cells with biotinylated, purified, recombinant, tumor-associated MUC1 glycoforms 18 ( Fig. 1a and Supplementary Fig. 1a ). MUC1-ST bound to primary monocytes and macrophages and acute myeloid leukemia cell lines ( Fig. 1a-e ). This interaction was lost after MUC1-ST was treated with neuraminidase to generate MUC1 carrying non-sialylated core 1 glycans (MUC1-T) ( Fig. 1b-d) , which demonstrated that the binding was dependent upon sialic acid. The binding also increased over time, with maximum binding occurring at 5 h, and with increasing concentrations of MUC1-ST ( Supplementary Fig. 1b,c) , but was calcium independent (Fig. 1f) . Moreover, the binding was enhanced when cells were pre-treated with neuraminidase ( Supplementary Fig. 1d ), which removes competing cis-binding sialic acid sites from the surface of the cells. Such a binding pattern is characteristic of binding to Siglecs 11 , and indeed MUC1-ST bound recombinant Siglec-3, Siglec-7, Siglec-9 and Siglec-10, with the greatest binding seen for Siglec-9 ( Fig. 1g) . Although Siglec-3, Siglec-7 and Siglec-9 were expressed by monocytes and macrophages ( Supplementary Fig. 1e ), a blocking antibody to Siglec-9 (anti-Siglec-9) inhibited 80-95% of the binding of MUC1-ST to these cells ( Fig. 1h,i, Supplementary Fig. 1f and Supplementary  Table 1 ), which indicated that this was the dominant binding Siglec. We note that this antibody to Siglec-9 can also act as an activating antibody, as it recognizes the sialic-acid-binding site on . Notably, Siglec-9 bound to the human breast cancer cell line T47D, which expresses MUC1 carrying sialylated core 1 glycans 21 (Fig. 1j) . However, a multivalent polymer of sialylated core 1 glycans bound only weakly to monocytes, and this interaction was not inhibited by anti-Siglec-9 ( Supplementary Fig. 1g ). This finding suggested a contribution of the protein backbone to the binding specificity of Siglec-9 that acted possibly by defining a specific spacing of the sialic acids. Thus, MUC1-ST specifically bound to Siglec-9 on primary monocytes and macrophages.
MUC1-ST binding induces the secretion of various factors
To determine whether binding of MUC1-ST induced a cellular response, we assayed for soluble factors released from cultured primary monocytes after they bound recombinant MUC1-ST. MUC1-ST induced monocytes to secrete several factors associated with inflammation and tumor progression ( Fig. 2a and Supplementary Fig. 2a ).
We used ELISA to confirm the induced secretion of interleukin 6 (IL-6), the macrophage-stimulating cytokine M-CSF and the plasminogen-activator inhibitor PAI-1 ( Fig. 2b-d) . This induction was dependent upon recognition of sialic acid, as MUC1-T failed to induce such secretion ( Fig. 2b-d) ; in addition, blocking the binding of MUC1-ST through the use of a Siglec-9-specific antibody significantly decreased the secretion of these three factors ( Fig. 2e-g) .
Some of the factors secreted after engagement of Siglec-9 by MUC1-ST ( Fig. 2a and Supplementary Fig. 2a ) have the potential to remodel the microenvironment by recruiting monocytes and neutrophils (CXCL5, CCL2, CCL3, CXCL1, IL-8 and PAI-1) 22, 23 , to induce angiogenesis (PAI-1 and IL-8) 24, 25 or to degrade the extracellular matrix (MMP9 and PAI-1) 26 . The incubation of monocytes with T47D cells, which express MUC1-ST, also induced the release of PAI-1 ( Fig. 2h) .
As a control, we used T47D cells that had been transfected to express the glycosyltransferase C2GnT1, which competes with the sialyltransferase that forms the 'ST' glycan; this results in the expression of MUC1 carrying branched core 2 glycans that are representative of the glycosylation of MUC1 by normal mammary epithelial cells 21 .
When monocytes were incubated with those transfected control T47D cells, their secretion of PAI-1 was significantly lower than that of monocytes incubated with wild-type T47D cells expressing MUC1-ST ( Fig. 2h) . In response to MUC1-ST, monocytes also produced pro-inflammatory nitric oxide (NO) (Fig. 2i) , a product of the 
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No cell line T47D T47D (core 2) npg A r t i c l e s arginine-processing enzyme 27 . This NO release was reduced partially, although not significantly (because of donor variation), by anti-Siglec-9 ( Fig. 2i) . Thus, engagement of Siglec-9 by MUC1-ST induced the release of factors that can promote tumor growth and modulate the microenvironment.
MUC1-ST binding influences myeloid differentiation
As IL-6 and NO are known modulators of cellular differentiation 28, 29 , we assessed the effects of MUC1-ST on the differentiation of monocytes into macrophages or dendritic cells (DCs). Monocytes were differentiated into macrophages for 7 d with M-CSF, followed by treatment with lipopolysaccharide (LPS) and IFN-γ, which generated 'M(LPS+IFN-γ)' cells 30 (historically defined as 'M1-like macrophages').·When MUC1-ST was added at day 0 of the culture, the differentiated macrophages showed lower surface expression of the co-stimulatory molecule CD86 (Fig. 3a,b ) and significantly reduced secretion of IL-12 (by over tenfold; Fig. 3c ) relative to that of monocytes differentiated into macrophages in the absence of MUC1-ST. These significant changes in phenotype were rescued in part by blocking antibody to Siglec-9 or to the IL-6 receptor ( Fig. 3a-c) . We next induced primary monocytes to differentiate into macrophages in the presence or absence of MUC1-ST and then cultured the cells with autologous T cells that had been stimulated with antibody to the invariant signaling protein CD3 (anti-CD3) and antibody to the co-stimulatory receptor CD28 (anti-CD28). Proliferation of the CD8 + T cells, indicated by a decrease in the cell-proliferation dye eFluor 670 (as assessed by flow cytometry), was significantly inhibited when the T cells were cultured together with the macrophages differentiated from monocytes in the presence of MUC1-ST relative to the proliferation of those cultured with macrophages differentiated from monocytes in the absence of MUC1-ST ( Fig. 3d) . Moreover, the CD8 + T cells cultured with macrophages differentiated in the presence of MUC1-ST showed less activation, as demonstrated by their lower expression of the activation markers CD25 and CD69, than that of CD8 + T cells cultured with macrophages differentiated in the absence of MUC1-ST ( Fig. 3e,f) . This inhibition of activation was reversed by the presence of antibody to Siglec-9 or to the IL-6 receptor α-chain (Fig. 3f) . The effect of anti-Siglec-9 alone might be explained by the expression of Siglec-9 on a subset of T cells 19 . However, when monocytes were differentiated into macrophages in the presence of MUC1-ST and anti-Siglec-9 and then were cultured with autologous T cells stimulated with anti-CD3 and anti-CD28, activation of the T cells was brought back to that of CD8 + T cells cultured with isotype-matched control antibody plus macrophages differentiated in the absence of MUC1-ST ( Fig. 3f) .
Monocytes differentiated into immature DCs with IL-4 and the granulocyte-and macrophage-stimulating cytokine GM-CSF in the presence of MUC1-ST displayed lower expression of CD86 than that of their counterparts differentiated into DCs in the absence of MUC1-ST (Supplementary Fig. 2b ) and, when matured with LPS, had lower expression of CD86 and the lectin transmembrane receptor CD83 than that of their counterparts differentiated into DCs in the absence of MUC1-ST ( Supplementary Fig. 2c ), as observed previously 31 . Treatment with anti-Siglec-9 or anti-IL-6 significantly reversed this downregulation of CD86 expression by immature and mature DCs (P < 0.05; Supplementary Fig. 2d-f ) and partially reversed the downregulation of CD83 expression by mature DCs (data not shown). Thus, the binding of MUC1-ST to monocytes induced a pro-inflammatory phenotype that can recruit immune cells into a tumor, induced the secretion of factors associated with tumor progression and induced the differentiation of monocytes into macrophages and DCs with lower CD8 + T cell-stimulatory capacity.
Binding of MUC1-ST to macrophages induces a TAM phenotype
We assayed the secretion of proteins by monocyte-derived macrophages when these macrophages were treated with MUC1-ST ( Fig. 4a) . Similar to monocytes, macrophages treated with MUC1-ST had more secretion of M-CSF ( Fig. 4b) and PAI-1 (Fig. 4c) , as well as of the protease CHI3L1 ('chitinase-3-like 1') ( Fig. 4a) , than that of untreated macrophages. In addition, secretion of epidermal growth factor (EGF) by macrophages treated with MUC1-ST was greater than that of macrophages treated with MUC1-T or no MUC1 (Fig. 4d) . Production of these tumor-progression-associated factors 24 was dependent upon Siglec-9, although the changes in EGF secretion were not significant (due to donor variation) ( Fig. 4e-g) . Notably, as with monocytes, we detected increased secretion of PAI-1 after co-culture of macrophages with MUC1-ST + T47D cells (Fig. 4h) . Moreover, the secretion of PAI-1 by macrophages cultured with T47D cells expressing MUC1 carrying branched core 2 glycans 21 was significantly lower than that of macrophages cultured with MUC1-ST + T47D cells (Fig. 4h) . However, unlike results obtained for MUC1-ST-treated monocytes, the secretion of chemokines associated with immunomodulation and cytokines by macrophages treated with MUC1-ST + isotype + isotype +anti-Siglec-9
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+anti-IL-6Rα Anti-IL-6Rα npg was not lower than or different from that of untreated macrophages (Fig. 4a) . Thus, monocytes and macrophages 'educated' by MUC1-ST and Siglec-9 displayed distinct secretomes. MUC1-ST-treated macrophages had higher expression of the mannose receptor CD206 and the scavenger receptor CD163 than that of untreated macrophages (Fig. 5a) . The expression of these markers is associated with TAMs 32 . Moreover, MUC1-ST-treated macrophages had higher expression of PD-L1 than that of untreated macrophages (Fig. 5a) , although they had only slightly higher PD-L2 expression (data not shown). These phenotypic changes were all 'rescued' by blockade of the binding of MUC1-ST to macrophages via anti-Siglec-9 (Fig. 5a) . In addition, treatment of macrophages with MUC1-ST increased the expression of mRNA encoding IDO by 10-to 25-fold relative to its expression by untreated macrophages (Fig. 5b,c) , an effect that was also 'rescued' via anti-Siglec-9 (Fig. 5b,c) . IDO catalyzes the rate-limiting step in the metabolism of tryptophan, A r t i c l e s and there was a higher concentration of the tryptophan metabolite kynurenine in macrophages treated with MUC1-ST than in untreated macrophages (Fig. 5d) . The activity of IDO inhibits the proliferation and induces apoptosis of T cells 33 . Moreover, increased expression of PD-L1 enhances the engagement of PDL-1 by its receptor PD-1 on activated T cells and inhibits their function 34 . Macrophages that had been 'educated' with MUC1-ST exhibited a diminished ability to stimulate the proliferation and IFN-γ secretion of allogeneic CD8 + T cells relative to that of macrophages that had not been thus 'educated' , with these effects being inhibited by the Siglec-9-blocking antibody (Fig. 5e,f) . To investigate the role of PD-L1 in the inhibition of CD8 + T cell proliferation, we used the PD-1-blocking antibody pembrolizumab to inhibit the binding of PD-L1 to PD-1 on the T cells. However, pembrolizumab was unable to inhibit the reduction in T cell proliferation induced by 'MUC1-ST-educated' macrophages ( Fig. 5g) ; moreover, when the interaction of PD-L1 with PD-1 was inhibited with pembrolizumab, the decrease in IFN-γ observed above was not 'rescued' (Fig. 5h) . Thus, in this in vitro system in which the T cells were not responding to a specific antigen, PD-L1 did not contribute to the decrease in T cell proliferation induced by 'MUC1-ST-educated' macrophages. This MUC1-ST-induced profile of expression and functional activity is indicative of TAMs, which have a role in promoting tumor progression 35, 36 .
Binding of MUC1-ST to Siglec-9 induces activation of MEK-ERK
To investigate the intracellular effects of the binding of MUC1-ST, we first assessed whether MUC1-ST was able to induce phosphorylation of the ITIM of Siglec-9 and thereby induce intracellular inhibitory signals 12 . We hypothesized that this possibility was likely, as the repeated glycans found on MUC1 should be able to crosslink Siglec-9. Unexpectedly, instead of promoting phosphorylation, we found MUC1-ST inhibited the basal phosphorylation of the Siglec-9 ITIM in monocytes and macrophages (Fig. 6a,b) . Notably, antibodyinduced crosslinking of Siglec-9 did induce phosphorylation (Fig. 6a) . Furthermore, phosphorylation of SHP-1, which is recruited by phosphorylated Siglec-9 (ref. 12) , was not observed after binding of MUC1-ST to Siglec-9 on primary monocytes (Fig. 6c) . However, phosphorylation of SHP-1 was observed when Siglec-9 was activated via antibody cross-linking (Fig. 6c) . No activation of SHP-2 was observed (data not shown). That finding was in contrast to results obtained by the engagement of Siglec-9 with other, as-yet-unknown ligands present on tumor cells, for which recruitment of SHP-1 was npg observed 15 . Moreover, studies of a mouse tumor model with mice deficient in Siglec-E (the mouse Siglec with the most similarity to human Siglec-9) have shown that expression of Siglec-E is associated with a decrease in alternatively activated macrophages 15 . Engagement of Siglecs has also been show to inhibit calcium flux 37, 38 . We therefore investigated the triggering of calcium flux when MUC1-ST engaged Siglec-9. When monocytes or macrophages were treated with MUC1-ST, calcium flux was induced that peaked at 30 s (Fig. 6d) . This calcium flux was completely dependent on the engagement of Siglec-9 by MUC1-ST ( Fig. 6e) . Calcium flux was also observed when monocytes and T47D cells came into contact with each other (Fig. 6f) . This response was inhibited by anti-Siglec-9 and was not seen in T47D cells expressing normal branched core 2 glycans (Fig. 6f) .
As binding of MUC1-ST to Siglec-9 did not induce phosphorylation associated with inhibitory signaling but instead induced calcium flux, which is associated with activating signals 38 , we investigated downstream signaling after binding of MUC1-ST to Siglec-9. To explore this possibility, we assayed the production of PAI-1 and M-CSF by 'MUC1-ST-educated' monocytes and macrophages. As expected, the secretion of PAI-1 and M-CSF was significantly inhibited by the calciumchannel inhibitor verapamil ( Fig. 6g-j) . Intracellular calcium flux can lead to activation of the MEK-ERK pathway 38 . When monocytes or macrophages were incubated with MUC1-ST in the presence of the highly selective MEK inhibitor PD98059 (ref. 39) , the secretion of PAI-1 and M-CSF was significantly inhibited relative to their secretion by monocytes and macrophages incubated with MUC1-ST without this inhibitor ( Fig. 6g-j) . Moreover, the repression of T cell proliferation by MUC1-ST-treated macrophages was partially overcome when MEK signaling was inhibited in the macrophages (Fig. 6k) .
Thus, we have identified an activating role for Siglec-9 after the binding of MUC1-ST. On the basis of our results, we have generated a model of how MUC1-ST can modulate the tumor microenvironment via engagement of Siglec-9 (Supplementary Fig. 3 ).
DISCUSSION
The majority of solid tumors contain infiltrating immune cells that are unable to eliminate the tumor and, in many cases, promote tumor progression 1 . TAMs are some of the most abundant immune cells found in tumors; their presence correlates with metastasis and poor prognosis 35, 36, 40, 41 . It has been proposed that for tumors to thrive, they need to produce factors that can recruit and 'educate' monocytes and repolarize resident macrophages into TAMs 41 . Here we have identified MUC1-ST as a myeloid-cell-modulating factor and a driver of TAM formation, as demonstrated by the higher expression of CD206, CD163, IDO and PD-L1 in cells treated with MUC1-ST than in untreated control cells. The finding that the binding of MUC1-ST to Siglec-9 increased expression of PD-L1 by macrophages was an important observation, as immune-system-checkpoint inhibitors are showing extremely promising results in the clinic 42 . The degree of increase in PD-L1 expression did differ among the healthy donors and ranged from 1.5-fold to over 7-fold. Relevant to this observation is the fact that even modest effects on the expression of PD-L1 can lead to tumor regression in mouse models 43 , so changes up to 7-fold have the potential to be very relevant to tumor growth. Additionally, these macrophages with a TAM-like phenotype were able to inhibit the proliferation and activation of CD8 + T cells. However, the reduction in the proliferation of T cells seen in our system did not appear to be due to the upregulation of PD-L1 expression on A r t i c l e s 'MUC1-ST-educated' macrophages, as this was not inhibited by the PD-1-blocking antibody pembroluzumab. The PD-1-PD-L1 checkpoint is not active in the initial T cell-activation stage but instead acts on effector cells that recognize antigen 44 . Although the PD-L1 expressed by 'MUC1-ST-educated' macrophages did not have a role in our in vitro assays in which the proliferation of T cells was not antigen specific, this finding does not exclude the possibility of a role for PD-L1 in cancer in which tumors can be infiltrated with antigen-specific CD8 + T cells. Moreover, engagement of Siglec-9 on monocytes and macrophages by MUC1-ST induced increased secretion of proteins involved in disease progression. Thus, this MUC1-ST-Siglec-9 axis has a role in orchestrating a tumor-permissive environment. Aberrant glycosylation is a hallmark of cancer that often results in increased sialylation 3, 4, 6 , which has been shown to result in the engagement of Siglecs [14] [15] [16] . Individual Siglecs (except for Siglec-4) are expressed by different subset of cells of the immune system, which leads to an overlapping and complex pattern of expression 11 . Siglec-9 is expressed by macrophages and monocytes, as well as by neutrophils, some B cells, a subset of T cells and a subset of natural killer cells. Ligands for Siglec-7 and Siglec-9 are expressed on tumor cells 14, 15 , and their engagement inhibits natural-killer-cell activity 14, 16 . When tumor cells are incubated with neutrophils, the activation of the neutrophils is inhibited in a Siglec-9-dependent manner, with increased killing of tumor cells in the presence of a Siglec-9-blocking antibody 15 . Mucins carry a very large number of O-linked glycans, the composition of which changes with malignancy, which results in the expression of shorter sialylated glycans 4 with the potential to engage Siglecs. MUC16 has been identified as a ligand for Siglec-9 (ref. 45) , as have mucins isolated from a colon carcinoma cell line 46 . MUC1, however, is the mucin most widely expressed in cancers derived from epithelial cells (adenocarcinomas), and the MUC1-ST glycoform is a dominant surface feature. MUC1 carrying undefined glycans binds to Siglec-9, which results in increased MUC1 signaling and growth of the MUC1-expressing tumor cells in vitro 17 . Infiltration of Siglec-9-expressing cells into MUC1-expressing tumors has been observed in vivo 17 . However, that study 17 did not investigate the effect on the immune cells of the engagement of Siglec-9 by MUC1. The availability of purified recombinant MUC1 carrying defined glycans 18 has allowed its use as a ligand here for study of the effects on myeloid cells of the binding of MUC1-ST to Siglec-9. The effects observed with this soluble MUC1-ST have been confirmed with the breast-cancer cell line T47D, which expresses endogenous MUC1 carrying the 'ST' glycan 21 .
MUC1 can also be expressed by activated T cells but not by resting T cells, although this level of expression is at least 50 times lower than that of breast-cancer cells 47 . MUC1 has also been seen on macrophages and DCs. However, the O-linked glycosylation pattern of these cells changes with the activation state 48, 49 , with activated T cells carrying core 2 glycans rather than the sialylated core 1 glycans ('ST') that we have shown bound to Siglec-9.
In contrast to classical Siglec engagement, which results in the recruitment and activation of SHP-1 or SHP-2 (ref. 12), engagement of Siglec-9 by MUC1-ST did not induce phosphorylation of this Siglec or SHP-1 but induced the transmission of activating signals. The binding of MUC1-ST to Siglec-9 on monocytes and macrophages induced changes that would affect the microenvironment to promote tumor growth and would thereby act as an immunomodulator. The mechanism involved was demonstrated to act via the induction of calcium flux, which led to activation of the MEK-ERK pathway. Understanding the mechanisms that contribute to immunosuppression by myeloid cells might help in the development of new myeloid-cell-checkpoint inhibitors, such as anti-Siglec-9 immunotherapy.
The sialyltransferase ST3Gal-I is responsible for the addition of sialic acid to the core 1 glycan that forms 'ST' 6 . This enzyme is overexpressed in breast and other carcinomas and catalyzes the formation of short sialylated side chains. In breast cancers, the cyclooxygenase COX-2 can increase ST3Gal-I expression 50 . The principal metabolite of COX-2 is the prostaglandin PGE 2 , and COX-2 is induced by inflammatory mediators (such as IL-6). Thus, the chronic inflammation induced by the binding of MUC1-ST to Siglec-9 + myeloid cells would maintain continued expression of the MUC1-ST glycoform via induced expression of COX-2. This positive feedback loop would maintain the induction of TAMs and the continued modulation of the microenvironment. Thus, we have determined a vital function for aberrant O-linked glycosylation in tumor growth and progression.
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